Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients

INTRODUCTION: Doravirine (DOR) is an investigational NNRTI (aka MK-1439) that retains activity against common NNRTI-resistant mutants. We have previously reported the Part 1 results from a two-part, randomized, double-blind, Phase IIb study in ART-naïve HIV-1-positive patients [1]. At doses of 25, 5...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatell, Josep M, Morales-Ramirez, Javier O, Hagins, Debbie P, Thompson, Melanie, Keikawus, Arasteh, Hoffmann, Christian, Rugina, Sorin, Osiyemi, Olayemi, Escoriu, Simona, Dretler, Robin, Harvey, Charlotte, Xu, Xia, Teppler, Hedy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Oral Presentation – Abstract O434
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224904/
https://www.ncbi.nlm.nih.gov/pubmed/25394041
http://dx.doi.org/10.7448/IAS.17.4.19532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224904/
https://www.ncbi.nlm.nih.gov/pubmed/25394041
http://dx.doi.org/10.7448/IAS.17.4.19532

Ejemplares similares